Diabetes and Incretin-based Therapy
نویسندگان
چکیده
منابع مشابه
Incretin-based Therapy in the Management of Type 2 Diabetes
Type 2 diabetes is a progressive disease due to reduced beta cell mass, which results in the failure of traditional treatment and the need for more intensive therapeutical measures to maintain a good glycaemic control. Within the last decade there was a preoccupation for developing new classes of drugs to achieve several goals: glycaemic control, weight loss and to preserve residual beta cell m...
متن کاملIntegrating incretin-based therapy into type 2 diabetes management.
LEARNING OBJECTIVES 1. Explain the concept of the incretin effect and describe defects in incretin secretion and incretin action that occur in type 2 diabetes mellitus (T2DM) 2. Provide an overview of the rationale and role of incretin-based therapy as described in current practice guidelines for the management of patients with T2DM 3. Compare the efficacy, safety, and tolerability of the incre...
متن کاملEvidence-based practice use of incretin-based therapy in the natural history of diabetes.
The incretin class of anti-hyperglycemic agents, including glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-inhibitors, is an important addition to the therapeutic armamentarium for the management of appropriate patients with type 2 diabetes mellitus as an adjunct to diet and exercise and/or with the agents metformin, sulfonylureas, thiazolidinediones, or any combination there...
متن کاملNew drugs for the treatment of diabetes: part II: Incretin-based therapy and beyond.
This is the second of a 2-part series focusing on newer therapies for type 2 diabetes and their cardiovascular implications. In the first segment, we reviewed the thiazolidinediones, highlighting emerging data concerning their cardiovascular effects, both positive and negative. Here, we present a corresponding discussion of the newest antihyperglycemic category, modulators of the incretin syste...
متن کاملAddition of incretin therapy to metformin in type 2 diabetes.
Incretin-based therapies offer a new approach for the management of type 2 diabetes, with a mechanism of action distinct from any existing class of glucose-lowering agents. These drugs improve the body's ability to control blood glucose by increasing active concentrations of glucagon-like peptide-1 (GLP-1). Two approaches have been used to enhance the action of GLP-1. First, incretin mimetics (...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: The Journal of Clinical Endocrinology & Metabolism
سال: 2007
ISSN: 0021-972X,1945-7197
DOI: 10.1210/jcem.92.4.9998